参考文献/References:
[1]de Franchis R.Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J].Journal of Hepatology,2010,53(4):762-768.
[2]Garcia-Tsao G,Sanyal AJ,Grace ND,et al.Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J].Hepatology,2007,46(3):922-938.
[3]de Franchis R.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].Journal of Hepatology,2015,63(3):743-752.
[4]Angeli P,Gines P,Wong F,et al.Diagnosis and management of acute kidney injury in patients with cirrhosis:revised consensus recommendations of the International Club of Ascites[J].Gut,2015,64(4):531-537.
[5]Moreau R,Durand F,Poynard T,et al.Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome:a retrospective multicenter study[J].Gastroenterology,2002,122(4):923-930.
[6]Rodriguez E,Elia C,Sola E,et al.Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis[J].Journal of Hepatology,2014,60(5):955-961.
[7]Kang YJ,Bae EJ,Hwang K,et al.Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis[J].Springerplus,2013,2(1):519.
[8]Kim SE,Jung DM,Park JW,et al.Baseline Renal Function Predicts Hyponatremia in Liver Cirrhosis Patients Treated with Terlipressin for Variceal Bleeding[J].Gastroenterol Res Pract,2017,2017:7610374.
[9]Sola E,Lens S,Guevara M,et al.Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension[J].Hepatology,2010,52(5):1783-1790.
[10]Yim SY,Seo YS,Jung CH,et al.Risk Factors for Developing Hyponatremia During Terlipressin Treatment:A Retrospective Analyses in Variceal Bleeding[J].Journal of Clinical Gastroenterology,2015,49(7):607-612.
[11]Hansen EF,Strandberg C,Hojgaard L,et al.Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs[J].Journal of Hepatology,1999,30(3):503-510.
[12]Boyer TD,Sanyal AJ,Garcia-Tsao G,et al.Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS)type 1:relationship of serum creatinine to hemodynamics[J].Journal of Hepatology,2011,55(2):315-321.
[13]Krag A,Bendtsen F,Pedersen EB,et al.Effects of terlipressin on the aquaretic system:evidence of antidiuretic effects[J].American Journal of Physiology Renal Physiology,2008,295(5):F1295-F1300.
[14]Angeli P,Wong F,Watson H,et al.Hyponatremia in cirrhosis:Results of a patient population survey[J].Hepatology,2006,44(6):1535-1542.
[15]D'Amico G,Pagliaro L,Bosch J.Pharmacological treatment of portal hypertension:an evidence-based approach[J].Seminars in liver disease,1999,19(4):475-505.
[16]Escorsell A,Ruiz del Arbol L,Planas R,et al.Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding:the TEST study[J].Hepatology,2000,32(3):471-476.
[17]Feu F,Ruiz del Arbol L,Banares R,et al.Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage.Variceal Bleeding Study Group[J].Gastroenterology,1996,111(5):1291-1299.
[18]Lo GH,Chen WC,Wang HM,et al.Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices[J].Gut,2009,58(9):1275-1280.
[19]Bruha R,Marecek Z,Prochazka V,et al.Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices[J].Hepato-gastroenterology,2009,56(90):390-394.
[20]Chang TT,Lee FY,Tsai YT,et al.A randomized controlled study of low-dose and high-dose terlipressin in the control of acute oesophageal variceal haemorrhage[J].Journal of Gastroenterology and Hepatology,1991,6(5):481-484.
[21]Zaki SA.Terlipressin-induced hyponatremic seizure in a child[J].Indian Journal of Pharmacology,2013,45(4):403-404.
[22]Hyun JJ,Seo YS,Lee KG,et al.Terlipressin-induced hyponatremic seizure[J].Scandinavian Journal of Gastroenterology,2010,45(4):501-504.
[23]Dunwoodie E,Jowett S.Terlipressin causing a hyponatraemic seizure[J].Scandinavian Journal of Gastroenterology,2007,42(5):665.
[24]Sharma P,Singh S,Sarin SK.Hyponatremia in patients with acute variceal bleeding treated with terlipressin[J].Hepatology,2011,53(2):714.
相似文献/References:
[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Journal of Medical Information,2018,31(09):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Journal of Medical Information,2022,35(09):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[3]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Journal of Medical Information,2019,32(09):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[4]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(09):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[5]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(09):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[6]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[7]王翔翔,刘明忠,杨中秋,等.腹腔镜与开腹脾切除贲门周围血管离断术治疗肝硬化门静脉高压脾肿大的临床对比[J].医学信息,2019,32(01):109.[doi:10.3969/j.issn.1006-1959.2019.01.033]
WANG Xiang-xiang,LIU Ming-zhong,YANG Zhong-qiu,et al.Clinical Comparison of Laparoscopic and Open Spleen Resection of the Pericardium in the Treatment of Cirrhosis with Portal Hypertension and Splenomegaly[J].Journal of Medical Information,2019,32(09):109.[doi:10.3969/j.issn.1006-1959.2019.01.033]
[8]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Journal of Medical Information,2022,35(09):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[9]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(09):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[10]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Journal of Medical Information,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[11]张津生.肝硬化门静脉高压CT和磁共振成像的表现[J].医学信息,2021,34(14):57.[doi:10.3969/j.issn.1006-1959.2021.14.016]
ZHANG Jin-sheng.CT and MRI Features of Portal Hypertension in Liver Cirrhosis[J].Journal of Medical Information,2021,34(09):57.[doi:10.3969/j.issn.1006-1959.2021.14.016]